KeyCorp Analysts Increase Earnings Estimates for PharMerica Co. (PMC)
PharMerica Co. (NYSE:PMC) – Equities research analysts at KeyCorp upped their FY2017 earnings per share estimates for PharMerica in a research report issued to clients and investors on Monday. KeyCorp analyst J. Gurda now expects that the company will post earnings of $1.90 per share for the year, up from their prior estimate of $1.85. KeyCorp also issued estimates for PharMerica’s FY2018 earnings at $2.05 EPS.
Separately, Zacks Investment Research upgraded PharMerica from a “sell” rating to a “hold” rating in a report on Wednesday, January 18th.
COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/17/keycorp-analysts-increase-earnings-estimates-for-pharmerica-co-pmc.html.
Shares of PharMerica (NYSE:PMC) opened at 25.85 on Wednesday. The stock has a market cap of $797.19 million, a price-to-earnings ratio of 38.58 and a beta of 1.10. The stock’s 50 day moving average price is $23.59 and its 200 day moving average price is $24.31. PharMerica has a one year low of $19.20 and a one year high of $28.72.
PharMerica (NYSE:PMC) last posted its earnings results on Wednesday, May 10th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.02. The company had revenue of $566.80 million during the quarter, compared to analyst estimates of $536.85 million. PharMerica had a return on equity of 10.40% and a net margin of 1.64%. PharMerica’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.45 earnings per share.
A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in PharMerica during the first quarter worth $121,000. US Bancorp DE raised its stake in PharMerica by 41.3% in the first quarter. US Bancorp DE now owns 7,121 shares of the company’s stock worth $167,000 after buying an additional 2,081 shares in the last quarter. Mason Street Advisors LLC raised its stake in PharMerica by 7.0% in the first quarter. Mason Street Advisors LLC now owns 7,200 shares of the company’s stock worth $168,000 after buying an additional 474 shares in the last quarter. Tudor Investment Corp ET AL raised its stake in PharMerica by 4.7% in the first quarter. Tudor Investment Corp ET AL now owns 8,602 shares of the company’s stock worth $201,000 after buying an additional 389 shares in the last quarter. Finally, Tudor Investment Corp Et Al bought a new stake in PharMerica during the fourth quarter worth $207,000. Institutional investors own 97.15% of the company’s stock.
PharMerica Company Profile
Receive News & Ratings for PharMerica Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Co. and related companies with MarketBeat.com's FREE daily email newsletter.